key: cord-0958121-5thvg7qs authors: Opota, Onya; Brouillet, René; Greub, Gilbert; Jaton, Katia title: Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples date: 2020-10-08 journal: Pathog Dis DOI: 10.1093/femspd/ftaa061 sha: 646d32875a9ebe1396be3431254683adb9036577 doc_id: 958121 cord_uid: 5thvg7qs OBJECTIVES: In order to cope with the rapid spread of the COVID-19 pandemic, we introduced on our in-house high-throughput molecular diagnostic platform (MDx Platform) a real-time reverse transcriptase PCR (RT-PCR) to detect the SARS-CoV-2 from any clinical specimens. The aim of this study was to compare the RT-PCR results obtain with the MDx Platform and the commercial assay cobas SARS-CoV-2 (Roche) on nasopharyngeal swab and other clinical specimens including sputum, bronchial aspirate, bronchoalveolar lavage and anal swabs. METHODS: Samples received in our laboratory from patients suspected of COVID-19 (n = 262) were tested in parallel with our MDx platform SARS-CoV-2 PCR and with the cobas SARS-CoV-2 test. RESULTS: The overall agreement between the two tests for all samples tested was 99.24% (260/262), which corresponded to agreements of 100% (178/178) on nasopharyngeal swabs, 94.6% (42/44) on lower respiratory tract specimen with a discordant result obtain for very high cycle threshold (Ct) value and 100% (40/40) on anorectal swabs. The Ct values for nasopharyngeal swabs displayed an excellent correlation (R(2)>96%) between both tests. CONCLUSIONS: The high agreements between the cobas SARS-CoV-2 test and the MDx platform supports the use of both methods for the diagnostic of COVID-19 on various clinical samples. Very few discrepant results may occur at very low viral load. teaching hospital [4] . The aim of this study was to compare the cobas SARS-CoV-2 (Roche, Rotkreuz, Switzerland) test and our MDx platform: i) to permit other laboratories to achieve the diagnostic of COVID-19, therefore increasing the overall testing capacity, ii) to serve as backup in case of breakdown or reagent storage, iii) and to evaluate the performance of the cobas test on respiratory specimens other that nasopharyngeal swabs and on anorectal swabs. Indeed, in cases of high positive pre-test probability and negative PCR on a nasopharyngeal specimen, a lower respiratory tract specimen might be performed. The need to test various clinical samples such as LRT or anorectal swabs quickly became paramount for patients with atypical clinical presentations; for instance, anorectal swabs were tested in case of predominant gastrointestinal symptoms or in specific situations such as donor screening in the context of fecal microbiota transplantation for instance [5] [6] [7] . Samples from patients with a suspected COVID-19 (n=262) were tested both using our inhouse high-throughput MDx platform and the cobas SARS-CoV-2 qualitative test (Roche). Nasopharyngeal and oropharyngeal swabs (n=178) were collected in Copan Universal Transport Medium System (UTM-RT) or BD™ Universal Viral Transport System (UVT). Lower respiratory tract (LRT) specimen (n=44) were liquefied using N-acetyl-L-cysteine prior analysis using the cobas 6800 system, or prior nucleic acid extraction using the MagNA Pure 96 instrument when samples are tested on our MDx Platform [8] [9] [10] [11] . Anorectal swabs (n=40) were collected as previously described [12] . The automated molecular diagnostic platform consists of the nucleic-acid extraction system MagNA Pure 96 instrument (Roche), associated to a liquid handling distribution system, the STARletR instrument (Hamilton, Cinnaminson, USA), two Hamilton instruments for the assembly of the 384-well PCR plates and two QuantStudio 7 (Applied Biosystems, Waltham, USA) [2, 8, 13] . For this comparison, the detection of the SARS-CoV-2 on the MDx platform was achieved using only the RT-PCR targeting the E gene using the primers and probes described by Corman and colleagues [3] . The concentration of forwards and reverse primers (300 nM) and Taqman probes (100 nM) were slightly reduced as compared to the E gene PCR of Corman and colleagues. Plasmids containing the target amplicons of the RT-PCR were obtained from RD-Biotech (Besançon, France) and were used as positive controls, and to determine the analytical limit of detection of the PCR as well as the reproducibility of the PCRs as previously described [2, 13, 14] . Another positive control, corresponding to SARS- CoV-2 RNA purified from cell culture supernatants, was received from the Institute of Virology of the University of Berlin, Charité [3] . The analytic sensitivity was determined with the positive control plasmids diluted from 100'000 to 1 DNA copies per reaction (Table S1 ). The intra-and inter-run reproducibility was assessed in five independent runs with dilutions of the plasmids corresponding to 100 and 10 DNA copies per reactions ( Figure S1 ). The specificity of the RT-PCR was assessed using 10 samples containing other seasonal coronavirus. The RT-PCR targeting the RdRP gene and the N-gene were also introduced according to Corman and colleagues but showed a significantly reduced sensitivity requiring further optimisation and was not used for this comparison [15] . The cobas SARS-CoV-2 qualitative tests were run on the cobas 6800 System (Roche) according to the manufacturer guidelines. Statistical analysis were performed using GraphPad Prism version 8.3.0 for Windows, GraphPad Software (San Diego, California, USA, www.graphpad.com). Cycle thresholds (Ct) were analysed using one-way ANOVA or using Bland-Altman analysis by ploting the difference between two measurements on the Y axis, and the average of the two measurements on the X axis. The degree of agreement was quantified by the kappa value. The data were obtained during a quality enhancement project at our institution. According to national law, the performance and publishing the results of such a project can be done without asking the permission of the competent research ethics committee. The SARS-CoV-2 RT-PCR that we aimed to introduce in our MDx platform targeting the E, RdRP and N gene were validated by Corman and colleagues [3] . We therefore decided to perform a rapid introduction and validation of these PCR to face the rapid spreading of COVID-19 in Europe. We first assessed the analytical sensitivity of the 3 real-time PCR using the positive control received from the Institute of Virology of the University of Berlin, Charité [3] corresponding to SARS-CoV-2 RNA purified from cell culture supernatants. The sensitivity of the test was evaluated for the 3 genes at ten-fold serial dilutions (10 3 , 10 2 , and 10 1 , respectively When we received the synthetic plasmid positive control for the E gene RT-PCR, the complete analytic sensitivity and reproducibility test, confirmed the reliability of the PCR. The analytic sensitivity was determined with the positive control plasmids diluted from 100'000 to 1 copies per reaction. The limit of detection (LOD) for the E gene assay was between 1 to 10 copies per reaction with respectively 36% and 100% hit rate. The intra-run variability, assessed by plotting the Ct values of the 5 replicates of the same run of amplification for plasmids dilutions corresponding to 100 and 10 copies per reaction, showed that the dispersion of each replicate did not exceed 2 standard deviation of the average (Fig. S1 ). The inter-run reproducibility was assessed in five independent runs with dilutions of the plasmids corresponding to 100 and 10 copies per reaction and also revealed that the dispersion of the average Ct value for each run did not exceed 2 SD of the average of all runs (Fig. S1 ). For the specificity, 10 samples containing other coronavirus (seasonal strains) were tested and showed 100% specificity without any unexpected amplification. Agreement between the cobas SARS-COV-2 and the MDx Platform on various clinical specimens. More than 10'000 SARS-CoV-2 test have been performed in 40 days when we received the kits to test the cobas SARS-CoV-2 assay on the cobas 6800 instrument already in use in our laboratory ( Figure 1A ). Figure 1A ). At the beginning of the COVID-19 epidemic and in the absence of test provided by industries we introduced a RT-PCR for the detection of the SARS-CoV-2 on our high-throughput open automated MDx platform according to our accredited R&D process [2] . This allowed us to achieve the diagnosis of COVID-19 for our hospital as well as other hospitals of our canton (Vaud) and four other neighbouring cantons, with more than 1'000 analysis performed in a single day ( 19 th March). After 40 days of use of our MDx platform, we could test the cobas SARS-CoV-2 kit on the cobas 6800 instrument already available in our diagnostic laboratory, which revealed an excellent agreement with our MDx platform on upper respiratory tract specimen, as reported [16] . We also observed a very good correlation between the semi-quantitative results (Ct value) of both tests. We thus introduced the cobas SARS-CoV-2 test in routine and could therefore use the two methods alternatively or in parallel. This was particularly useful to manage the stock of reagent and sporadic instruments breakdowns. The correlation between the semi-quantification using both test allow us to report Ct values and corresponding viral loads to the clinicians [17] . Reporting SARS-CoV-2 viral load was very useful for both patient care and infection control strategies [17] [18] [19] [20] . This was also very useful for RT-PCR results interpretation in the setting of repeated tests on the same patient or testing multiple specimen from the same patient (e.g URT versus or LRT, or URT versus anorectal swabs). Indeed, discrepant results could occur due to viral load at the limit of the detection of RT-PCR or because of the normal time course of the infection [21] . RT-PCR are very sensitive and have a detection limit of 100 to 1000 copies per ml of specimen [22] . The introduction of high-throughput SARS-CoV-2 RT-PCR systems was among the decisive interventions of molecular diagnostic laboratories to face the COVID-19 pandemic [4, 26] . However, when testing such a high number of specimen per day including different clinical specimen from the same patient, discrepant results might occur due to the normal evolution of the disease. To maintain the quality and the reliability of RT-PCR, such discrepant results can be identified and investigated using computer aided post-analytical software that are mandatory to handle such a high number of results [21] . Other clinical specimen are routinely analysed for the diagnostic of COVID-19 on our MDx platform but not using the cobas SARS-CoV-2 test because of limited volume available ( i.e. biopsy or CSF) or clotting issues (i.e blood) [11, 12] . Altogether, these data suggest that both the cobas-SARS-CoV-2 test and our MDx platform Sars-cov-2, a point in the storm Ten years of r&d and full automation in molecular diagnosis Detection of 2019 novel coronavirus (2019-ncov) by real-time rt-pcr Clinical microbiology laboratory adaptation to covid-19 emergency: Experience at a large teaching hospital in rome, italy Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests Epidemiologic features and clinical course of patients infected with sars-cov-2 in singapore Sars-cov-2 induced diarrhoea as onset symptom in patient with covid-19 Methods for real-time pcr-based diagnosis of chlamydia pneumoniae, chlamydia psittaci, and chlamydia abortus infections in an opened molecular diagnostic platform Added value of xpert mtb/rif ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting Added value of molecular assay xpert mtb/rif compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country Development of a high throughput pcr to detect coxiella burnetii and its application in a diagnostic laboratory over a 7-year period High prevalence of anorectal chlamydial infection in hiv-infected men who have sex with men in switzerland Improving the molecular diagnosis of chlamydia psittaci and chlamydia abortus infection with a species-specific duplex real-time pcr Genomics of the new species kingella negevensis: Diagnostic issues and identification of a locus encoding a rtx toxin Letter to the editor: Sars-cov-2 detection by real-time rt-pcr Clinical evaluation of the cobas sars-cov-2 test and a diagnostic platform switch during 48 hours in the midst of the covid-19 pandemic Viral load of sars-cov-2 across patients and compared to other respiratory viruses Quantitative detection and viral load analysis of sars-cov-2 in infected patients Clinical importance of reporting sars-cov-2 viral loads across the different stages of the covid-19 pandemic Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Computer-aided medical microbiology monitoring tool: A strategy to adapt to the sars-cov-2 epidemic and that highlights rt-pcr consistency Rapid establishment of laboratory diagnostics for the novel coronavirus sars-cov-2 in bavaria, germany Viral load kinetics of mers coronavirus infection Viral loads in clinical specimens and sars manifestations From donor to patient: Collection, preparation and cryopreservation of fecal samples for fecal microbiota transplantation Responding to covid-19 in istanbul: Perspective from genomic laboratory We thank all the staff of the Laboratory of Molecular Diagnostic of the Institute of Microbiology of the University of Lausanne.All the authors declare no conflict of interest related to this work.